The IJTLD provides a free-to-publish journal for authors (mainly in LMICs), who lack open access funding and conduct research on respiratory health.
The journal's coverage is distinct to IJTLD Open, which has a broader range of articles and scope. Please compare the Instructions for Authors for the two journals to ensure your article is appropriate for the IJTLD.
Individuals and Institutes can subscribe to the IJTLD online, simply e-mail us at subscription@theunion.org
Funding agencies have recently mandated that authors must publish exclusively in fully-OA journals.
We are committed to maintaining the IJTLD for authors in LMICs who lack OA funding, while also launching a new title, IJTLD OPEN, which covers a broader range of topics with additional article types.
To ensure we apply the same quality standards for open access publishing, both journals have the same Editorial Board with an identical peer review process and acceptance criteria. Before submitting, please check whether your article is better suited to the IJTLD or IJTLD Open.
The latest peer-reviewed articles on TB and HIV; respiratory diseases such as asthma and COPD; and the hazards of tobacco and air pollution. Recent coverage has expended to include COVID-19 and the interplay between TB-COVID-19 and other co-morbidities.
Individuals and institutes can subscribe to the IJTLD online – see our Subscription information or e-mail us at subscription@theunion.org for details.
We recently launched the IJTLD Clinical Standards for Lung Health, for optimal management of patients.
Thanks to the support of the Oskar-Helene-Heim Foundation and the Günther Labes Foundation, the first four Clinical Standards are Open Access and freely available to our global audience of clinicians and healthcare workers.
The series launched with Clinical standards for the assessment, management and rehabilitation of post-TB lung disease followed by Clinical standards for the diagnosis, treatment and prevention of TB infection, Clinical standards for the dosing and management of TB drugs and Clinical standards for drug-susceptible pulmonary TB.
Advertising or sponsoring content is an effective means of reaching clinicians, researchers, health workers, decision makers and students.
Sponsors can support the creation of a Collection or a Supplement on a relevant topic of interest, either in print or a digital collection of articles, for elevated visibility of your products and services.
Other opportunities include being involved in the creation of informative Posters, Infographics, or scientific Animations to clarify relevant biological processes.
IJTLD Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD and publishing them in full on our website, prior to their publication in the Journal. Read fast-track articles:
The rationale for cancer to be made a notifiable disease in India
In this Short Communication (to be published in the Q2 issue of PHA), the authors explain why the Ministry of Health in India should make cancer a notifiable disease.
TB disability and multimorbidity at the onset of treatment in Kenya, Uganda, Zambia and Zimbabwe
Ahead of World TB Day, we present an article that assesses the burden of multimorbidity and the effectiveness of referral pathways at the start of TB treatment across Kenya, Uganda, Zambia and Zimbabwe
Evaluating disability, comorbidities and risk factors after TB treatment: an 18–24 month follow-up in China
Ahead of World TB Day, we present an article that assesses disability, comorbidities and risk factors after TB treatment in China.
Other versions of the journal
The IJTLD has been published in several languages, and publishes the Union World Conference abstract book each year.
Contact
For all IJTLD enquiries, please contact the IJTLD Editorial Office.